Literature DB >> 2764534

Dose-dependent pharmacokinetics of mezlocillin in rats.

G L Jungbluth1, W J Jusko.   

Abstract

The pharmacokinetics of mezlocillin were examined in rats following bolus intravenous doses of 20 or 200 mg/kg. Mezlocillin exhibited bi- or triexponential disposition profiles, and the area under the concentration-time curve increased nonproportionally with dose similar to reported findings in humans. Apparent total, renal, and nonrenal clearances and the volume of distribution at steady-state all decreased by 45 to 50% with the higher dose, and the elimination half-life was longer (8 +/- 2 versus 15 +/- 3 min). Mezlocillin exhibits low saturable binding in rat serum, ranging from 20 to 40% bound. Pharmacokinetic parameters based on free drug demonstrated dose-dependent characteristics similar to those with total drug. Use of the volume of distribution from the low dose allowed calculation of the true mean residence time. The linear relationship between dose and mean residence time from free concentrations yielded pooled Michaelis-Menten parameters. These were used as initial estimates in the simultaneous nonlinear fitting of the low- and high-dose mean free concentrations to a three-compartment model with sequential distribution and Michaelis-Menten elimination to describe the nonlinearity of mezlocillin disposition further.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2764534      PMCID: PMC284242          DOI: 10.1128/AAC.33.6.839

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  A statistical method for the estimation of binding parameters in a complex system.

Authors:  R L Priore; H E Rosenthal
Journal:  Anal Biochem       Date:  1976-01       Impact factor: 3.365

2.  Mezlocillin pharmacokinetics. Comparison with ampicillin and influence of probenecid.

Authors:  L Verbist; T B Tjandramaga; R Verbesselt; P J De Schepper
Journal:  Arzneimittelforschung       Date:  1979

3.  Nonlinear mezlocillin kinetics due to dose-dependent metabolism.

Authors:  U Gundert-Remy; R Hildebrandt; A Stiehl; E Weber
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

4.  Kinetics of mezlocillin in patients with biliary t-tube drainage.

Authors:  U Gundert-Remy; D Förster; P Schacht; E Weber
Journal:  J Antimicrob Chemother       Date:  1982-01       Impact factor: 5.790

5.  Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations.

Authors:  P J McNamara; M Gibaldi; K Stoeckel
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  LAGRAN program for area and moments in pharmacokinetic analysis.

Authors:  M L Rocci; W J Jusko
Journal:  Comput Programs Biomed       Date:  1983-06

7.  Determination of the ureidopenicillins azlocillin, mezlocillin and bay K 4999 in plasma by high performance liquid chromatography.

Authors:  U Gundert-Remy; J X De Vries
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

8.  Biliary elimination of mezlocillin: an experimental and clinical study.

Authors:  J M Brogard; J Kopferschmitt; J P Arnaud; M Dorner; J La Villaureix
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

9.  Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment.

Authors:  A Mangione; F D Boudinot; R M Schultz; W J Jusko
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

10.  Mezlocillin enteral absorption in rabbits.

Authors:  K J Lavelle; M E Brier; G R Aronoff
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

View more
  4 in total

1.  Dose Dependencies and Biocompatibility of Renal Clearable Gold Nanoparticles: From Mice to Non-human Primates.

Authors:  Jing Xu; Mengxiao Yu; Chuanqi Peng; Phoebe Carter; Jia Tian; Xuhui Ning; Qinhan Zhou; Qiu Tu; Greg Zhang; Anthony Dao; Xingya Jiang; Payal Kapur; Jer-Tsong Hsieh; Xudong Zhao; Pengyu Liu; Jie Zheng
Journal:  Angew Chem Int Ed Engl       Date:  2017-12-05       Impact factor: 15.336

2.  Inhibition of flucloxacillin tubular renal secretion by piperacillin.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Br J Clin Pharmacol       Date:  2008-11       Impact factor: 4.335

Review 3.  Renal Clearable Luminescent Gold Nanoparticles: From the Bench to the Clinic.

Authors:  Mengxiao Yu; Jing Xu; Jie Zheng
Journal:  Angew Chem Int Ed Engl       Date:  2019-01-14       Impact factor: 15.336

Review 4.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.